Articles tagged "Immunosuppression"

2018 American Transplant Congress
The Impact of Childhood Solid Organ Transplantation on B-Cell Maturation
L. Ionescu,¹ T. Blydt-Hansen,² B. Foster,⁷ S. Mital,³ L. Hamiwka,⁵ U. Allan,³ V. Phan,⁴ P. Birk,⁶ C. Morgan,¹ S. Urschel.¹
¹U of Alberta, Edmonton, Canada; ²U of BC, Vancouver, Canada; ³Hospital for Sick Children, Toronto, Canada; ⁴U de Montreal, Montreal, Canada; ⁵U of Calgary, Calgary, Canada; ⁶U of Manitoba, Winnipeg, Canada; ⁷McGill University, Montreal, Canada.
Background:The developing immune system of childhood promotes better graft acceptance and longevity but also higher risk for infections and post-transplant (Tx) lymphoproliferative disorders. This may…
2018 American Transplant Congress
Influence of mTOR Inhibitors on Metabolic Outcomes One Year after Kidney Transplantation: The Role of Pre-Transplantation Diabetes
D. Cucchiari,¹ S. Karam,² P. Ventura-Aguiar,¹ J. Torregrosa,¹ F. Diekmann.¹
¹Renal Transplant Unit, Hospital Clínic, Barcelona, Spain; ²Department of Medicine, Saint George Hospital, Beirut, Lebanon.
INTRODUCTION: mTOR inhibitors alter lipids and carbohydrate metabolism in kidney transplant recipients. Little is known if there is any difference between patients who were already…
2018 American Transplant Congress
Genome-Wide Association Study of Tacrolimus Dose in Pediatric Solid Organ Transplant Recipients in the CNTRP POSITIVE Study
S. Min,¹ T. Papaz,¹ T. Blydt-Hansen,³ O. Lee,¹ U. Allen,¹ P. Birk,² H. Grasemann,¹ L. Hamiwka,⁴ C. Litalien,⁵ V. Ng,¹ R. Parekh,¹ K. Tinckam,⁶ S. Urschel,⁷ B. Foster,⁸ S. Mital.¹
¹The Hospital for Sick Children, Toronto, Canada; ²Winnipeg Children's Hospital, Winnipeg, Canada; ³BC Children's Hospital, Vancouver, Canada; ⁴Alberta Children's Hospital, Calgary, Canada; ⁵CHU Ste-Justine, Montreal, Canada; ⁶University Health Network, Toronto, Canada; ⁷Stollery Children's Hospital, Edmonton, Canada; ⁸Montreal Children's Hospital, Montreal, Canada.
PURPOSE: There are significant challenges in achieving therapeutic tacrolimus (Tac) concentrations after transplant. We explored variants associated with tacrolimus dose requirements in pediatric solid organ…
2018 American Transplant Congress
Long-Term Follow-Up of Pediatric Kidney Recipients Who Received Alemtuzumab Induction
D. Harriman, A. Chen, J. Rogers, R. Stratta, G. Orlando, A. South, J-.J. Lin, A. Farney.
Surgery, Pediatrics, Cardiovascular Sciences Center, Wake Forest Baptist Medical Center, Winston-Salem, NC.
Introduction: Experience with alemtuzumab (alem) depleting antibody induction has rarely been studied in the pediatric population, and reports that exist have limited follow-up. The purpose…
2018 American Transplant Congress
Regulatory Dendritic Cell (DCreg) Cell Infusion in Living Donor Liver Transplantation
A. Thomson, A. Humar, F. Lakkis, S. Styn, A. Zahorchak, C. Macedo, D. Metes.
Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Purpose: We have embarked on a first-in-human phase I/II safety and preliminary efficacy trial of donor-derived regulatory dendritic cells (DCreg) in living donor liver transplantation…
2018 American Transplant Congress
Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 9 Years Follow-Up
S. Narumi,¹ Y. Watarai,¹ N. Goto,² T. Hiramitsu,¹ M. Okada,¹ M. Tsujita,² K. Futamura,² M. Nishihira,³ T. Kobayashi.⁴
¹Transplant Surgery, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan; ²Transplant Nephrology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan; ³Nephrology, Masuko Memorial Hospital, Nagoya, Aichi, Japan; ⁴Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Purpose: Long-term efficacy and safety of everolimus (EVR) based immunosuppression for de novo kidney transplant recipient who were involved in A1202 study was evaluated in…
2018 American Transplant Congress
Novel Low Dosing of Rabbit Antithymocyte Globulin Preserves Excellent Outcomes and Improves the Value of Care in Low Risk Renal Transplantation
J. Dann, W. Ally, M. Bradley, J. Geyston, A. Agarwal.
University of Virginia Health System, Charlottesville, VA.
Elderly and non-sensitized renal transplant patients may benefit from lesser induction immunosuppression. This study evaluates three year clinical outcomes of a low risk renal transplant…
2018 American Transplant Congress
Adjunctive Corticosteroid Immunosuppression Improves Hyperbilirubinemia Following Liver Transplantation (OLT)
G. Malat, D. Reich, G. Xiao, M. Harhay, K. Ranganna, D. Lee, S. Guy, S. Munoz.
Drexel University, Philadelphia.
Background: Deceased donor orthotopic liver transplantation (OLT) can result in significant delayed function, manifesting as protracted hyperbilirubinemia, depending on the intensity of the ischemia/reperfusion injury…
2018 American Transplant Congress
Mycophenolic Acid Reduces BK Polyomavirus Replication in an In Vitro Model of Renal Tubular Epithelial Cells Infection
E. Favi,¹ S. Delbue,² C. Colico,¹ P. Ferrante,² S. Villani,² I. Perna,² N. Mondoni,² A. Giussani,¹ M. Ferraresso.¹
¹Kidney Transplantation, Fondazione IRCCS Ca' Granda, Milan, Italy; ²Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Background. BK virus (BKV) nephropathy is an important cause of allograft failure after kidney transplant. Immunosuppression is a recognized risk factor for BKV replication but…
2018 American Transplant Congress
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies
F. Shihab,¹ Y. Qazi,^1,2 V. Peddi,¹ D. Shaffer,¹ D. Kim,^1,2 K. McCague,³ D. Patel,³ S. Mulgaonkar.^1,2
¹US92 Study Group, Salt Lake City; ²TRANSFORM Study Group, East Hanover; ³Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Attainment of everolimus (EVR) target trough level (C0 3-8ng/mL) is crucial in achieving comparable efficacy-safety with EVR+reduced (r) calcineurin inhibitor regimen (CNI; tacrolimus [TAC]…